From Lab to Market: The Challenges of Biotech Scaling

The journey from a working result in a laboratory to a product on the market is where most of the real difficulty in biotech lives, and where many promising programs quietly fail. The science that succeeds at small scale must be reproduced, enlarged, and industrialized, and each step introduces problems that have nothing to do with whether the original idea was good. This essay explains the challenges of biotech scaling. It is educational and is not investment advice.

Why scaling is a distinct problem

A process that produces a small batch in a research lab is not the same as a process that produces commercial quantities reliably and affordably. Scaling is not simply doing more of the same. Yields shift, impurities behave differently, and steps that were trivial at small scale become critical at large scale. Treating scale-up as a formality is one of the most common and costly errors in the field, and it is a frequent reason that companies cannot supply their own pivotal trials.

Technology transfer

Moving a process from the bench to a manufacturing suite, or from one facility to another, is called technology transfer, and it is a discipline in its own right. Knowledge that lives informally in a few researchers' hands must be documented, standardized, and reproduced by a different team on different equipment. Things that worked because of unrecorded habits or specific local conditions can break when transferred. Programs that underestimate technology transfer discover, often at the worst moment, that their process does not travel.

For biologics, the process is the product

With small molecules, the same compound can in principle be made many ways. With biologics and living-cell therapies, small changes in the process can change the product itself, which makes scaling far more delicate. This is why regulators scrutinize manufacturing so closely for these therapies, and why manufacturing capability is treated as a durable competitive advantage, as argued in the analysis of the manufacturing moat. Scaling a biologic is as much a scientific problem as the original discovery.

Comparability and controlled change

Because the process shapes the product, any change to manufacturing must be shown not to have changed the product in ways that matter, a requirement called comparability. This turns every manufacturing improvement into a controlled exercise with its own evidence burden, rather than a quick fix. Comparability protects patients, but it also means that a company cannot casually alter its process to cut costs or boost yield late in development without risking its regulatory standing. Planning the process well early avoids painful comparability battles later.

Cost of goods and commercial viability

Scaling is not only about whether a product can be made, but at what cost. The cost of goods determines margin, pricing flexibility, and whether a therapy can be sold sustainably. A therapy that works but cannot be made affordably struggles to reach patients or to support a business. With the capitalized cost of development estimated at roughly 2.6 billion dollars per approved drug in 2013 terms, manufacturing economics are a decisive part of whether all that investment can ever be repaid (DiMasi, Grabowski, and Hansen, 2016).

Supply chain and single-source risk

Complex therapies often depend on specialized raw materials, and a single contaminated lot or a single failed supplier can halt a program. Building a resilient supply chain, with qualified backup sources and careful quality control, is part of scaling that rarely gets attention until something breaks. Industry data show how supply and manufacturing constraints affect the sector's ability to deliver (Silicon Valley Bank). A team that has mapped and hardened its supply chain holds a quiet resilience that competitors underestimate.

The pattern Scaling failures are common, well documented, and usually about execution and planning rather than the underlying science.

The takeaway for builders and investors

The lesson is that getting science to work is necessary but far from sufficient. Companies that treat scaling, technology transfer, comparability, and supply as core strategy, resourced early, are the ones that reach the market. Those that treat them as later logistics frequently stall at exactly the point where value should be realized. This is also why commercialization, covered in how to commercialize a biotech innovation, must be planned alongside development, and the underlying science is surveyed, for general readers, in the cancer research library. For how this is navigated in practice, see the advisory practice.

Why scaling should start before it seems necessary

The most important practical lesson about scaling is one of timing: the work should begin long before it appears urgent. Process decisions made early, when a therapy is still in early development, constrain everything that follows, and choices that seem convenient at small scale can become expensive or impossible to change once a program advances. A process locked in for early trials, then found unsuitable for commercial scale, may require comparability work that delays a program by years. Teams that bring manufacturing expertise into the room early, and design their process with commercial scale in mind from the start, avoid the most painful version of this problem. This runs against the instinct to defer manufacturing investment until the science is proven, but the companies that scale successfully tend to be the ones that resourced manufacturing as seriously as discovery from the beginning. Scaling is not a phase that happens at the end. It is a discipline that, done well, runs throughout development, and it is inseparable from the commercialization planning described in how to commercialize a biotech innovation.

Outsourcing is not the same as solving

Many biotechs address scaling by outsourcing manufacturing to contract organizations, which can be a sound choice, but it does not remove the underlying responsibility. The company still owns the process, the comparability obligations, and the supply risk, and a contract manufacturer's problems become the company's problems. Effective outsourcing requires the in-house expertise to choose partners well, transfer the process rigorously, and oversee quality, none of which is trivial. Companies that outsource manufacturing in the belief that it makes scaling someone else's problem often discover that they have added a coordination challenge on top of the technical one. The lesson is that outsourcing changes who runs the equipment, not who is accountable for the outcome, which is why even companies that do not build their own plants must take manufacturing seriously, as argued in the analysis of the manufacturing moat.